. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2013 May 22;22(9):10.1158/1055-9965.EPI-13-0341. doi: 10.1158/1055-9965.EPI-13-0341

Table 2.

Number of nonmelanoma skin cancer and melanoma events by overall trial and sensitivity analysis

Overall trial
	Number of cases (annualized %)		HR (95% CI)^a	P^b
	Intervention (N=19,541)	Comparison (N=29,294)
NMSC	1923 (1.28)	2984 (1.32)	0.98 (0.92, 1.04)	0.44
Melanoma	114 (0.07)	165 (0.07)	1.04 (0.82, 1.32)	0.78
Sensitivity analysis^c
	Number of cases (Annualized %)		HR (95% CI)^a	P^b
	Intervention	Comparison
NMSC	977 (1.27)	2470 (1.34)	0.99 (0.92, 1.07)	0.76
Melanoma	54 (0.07)	136 (0.07)	1.04 (0.75, 1.43)	0.83

All models were adjusted for age, assignment in the Hormone Therapy trial, and assignment in the Calcium/Vitamin D trial.

Two-sided (from Cox proportional hazards model).

Sensitivity analysis censored women who did not comply with trial requirements (e.g., intervention participants who missed an annual clinic visit, failed to participate in ≥9 of the 18 first year group sessions, or failed to participate in ≥2 of the 4 group sessions in subsequent years; or comparison participants who missed an annual clinic visit)